Shuttle Pharmaceuticals Holdings, Inc. (SHPH)

Market Cap	14.84M
Revenue (ttm)	n/a
Net Income (ttm)	-3.37M
Shares Out	13.80M
EPS (ttm)	-0.29
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	260,683
Open	1.14
Previous Close	1.11
Day's Range	1.07 - 1.15
52-Week Range	1.02 - 126.26
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	May 25, 2023

About SHPH

Shuttle Pharmaceuticals Holdings, Inc., through its subsidiary, Shuttle Pharmaceuticals, Inc., focuses on the discovery, development, and commercialization of drugs for sensitizing cancers to radiation therapy. Its products in clinical stage include Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and soft tissue sarcomas; and Doranidazole, an injectable hypoxic cell radiation sensitizer for treatment of pancreatic, lung, and liver cancers. The company was founded in 2012 and is based in Rockville, Maryland.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Aug 31, 2022
• Employees: 7
• Stock Exchange: NASDAQ
• Ticker Symbol: SHPH